MYC and AKT Cooperation in Prostate Cancer
Author Information
Author(s): Clegg Nicola J., Couto Suzana S., Wongvipat John, Hieronymus Haley, Carver Brett S., Taylor Barry S., Ellwood-Yen Katharine, Gerald William L., Sander Chris, Sawyers Charles L.
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
Does the cooperation between MYC amplification and PI3K-pathway alteration contribute to prostate cancer progression?
Conclusion
The study found that MYC amplification and PI3K-pathway alterations co-occur in human prostate tumors and that their cooperation accelerates cancer progression.
Supporting Evidence
- MYC amplification co-occurs with PI3K-pathway activation in human prostate tumors.
- Cooperation between MYC and AKT accelerates progression to invasive cancer in mouse models.
- Older MPAKT mice showed reduced sensitivity to mTOR inhibition, indicating additional genetic events.
Takeaway
This study shows that two important genes, MYC and AKT, work together to make prostate cancer grow faster.
Methodology
The study used genetically engineered mouse models and analyzed human prostate tumor samples for genetic alterations.
Limitations
The study primarily focused on mouse models and may not fully represent human prostate cancer complexities.
Participant Demographics
The study analyzed 194 human prostate tumors, including 37 metastatic cases.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website